INTRODUCTION:

Immunity is the capacity or power of the body and Cancer is uncontrolled growth of abdominal cells in the body. Cancer is second stage of death. The several measures such as surgical resection of tumors, Chemotherapy and radiotherapy used to cure the cancer. The therapeutics can minimize and inhibit cancer cells, They not able to effectively defeat cancers. (1) The immune system detect cancer cells in two ways:

1. Recognizing molecule uniquely expressed in cancer cells (tumor specific antigens).

2. Recognizing molecule that differentially expressed cancer cells relative to normal cells (tumors - associated antigens).

The efficacy of treatment for management of cancer, such radiation therapy and Chemotherapy, limited by accuracy of toxicities which deferent side effects expressed by cancer patients. Cancer immunotherapy described in 1995. (2) In 2018 Tasuku Honjo and james P Allison received the Nobel prize in physiology or medicine for discovery of cancer therapy, which inhibitions of negative immune regulations. (3) Immunotherapy is effective and promising treatment for cancer, selectivity and long-lasting effect and demonstrated improved survival and tolerance. (4) Immunotherapy includes various therapies such as monoclonal antibodies tumor cell vaccines, immune cell vaccines and adoptive cell therapy. Immunotherapy was hardness of patients own immune system to kill the cancer cells that reduce toxic effects of Chemotherapy and radiotherapy. (5) Monoclonal antibodies black cytotoxic T Lymphocyte-associated protein-4, programmed cell

death-1, dendritic cell vaccines, and chimeric antigen receptor T cell have tremendous success in clinical trials of cancer. The Immunotherapy is treatment that used part of person immune system to fight disease. (8) They are divided into two ways: Firstly is stimulating the natural defences of immune system work harder or smarter to find and attack cancer cells and second making substances in lab, that component are using them to help restore or improve immune system work to find and attack to cancer cells.

Immunotherapy:

Immunotherapy is treatment of disease by activating for biological therapy in suppressing of immune system. Cancer immunotherapy called as immune-oncology from of a cancer treatment that used the power of body immune system to removed, control and prevent cancer.

Type of immunotherapy:

There are various types of cancer immunotherapy used to treat cancer,

1. Checkpoint inhibitors

2. Chimeric antigen receptor T - cell therapy

3. Cancer vaccines

4. Monoclonal antibodies

1. Checkpoint inhibitors:

The checkpoint inhibitors drug take "breaks" of the immune system, which helps recognized and attack cancer cells. Checkpoint are proteins found T cell regulate, T cell respond to foreign calls.

The T cell circulate the body for signs of infection and disease in cancer immune system. Checkpoint function to monitor autoimmunity tissue damage due to immune by modulating costimulatory inhibitory signalling.

Side effects of checkpoint inhibitors:

1. Pneumonitis

2. Diarrhea

3. Kidney Infections

4. Rashes

5. Itchiness

6. Problem of some hormone laver

2. Chimeric antigen receptor T - cell therapy:

The therapy takes some T cell is patient blood mixes them special virus, that T cell attack to tumor cells and cell back to patients. (6) They find attack to kill the cancer.

Side effects of CAR T - Cell therapy:

1. Severe headaches

2. Seizures

3. Confusion

4. Swelling

3.Cancer vaccines:

They are repos modifiers working by restoring ability of immune system to fight cancer. They consists of therapeutic vaccines. (7) FDA was approved hepatitis B virus vaccines and human papilloma virus vaccines.

Side effects of cancer vaccine:

1. Headache

2. Nausea

3. Back pain

4. Joint pain

5. Fever

6. Fatigue

7. Chills

4. Monoclonal antibodies:

The entry of foreign substance into body, B - Lymphocytes becomes active and antibody production takes place in reorganization of foreign substances. (8) They useful in treatment of cancer because they designed to attack very specific parts of cancer cells.

Side effects of Monoclonal antibodies:

1. Fever

2. Nausea

3. Vomiting

4. Chills

5. Weakness

6. Diarrhea

7. Headache

Advantages of immunotherapy:

1. Immunotherapies work as all type of cancer cells.

2. Immunotherapy directly attack to the cancer cells.

3. In skin cancer don’t response well chemotherapy and radiation but well respond to immunotherapy.

4. It can make your immune system strong and fight any autoimmune disorder like fever and other health problems. (9)

5. Immunotherapy is a standard treatment.

6. It is more sophisticated against the cancer treatment.

7. Effective against fever because it’s target only in your immune system.

8. Some immunotherapy work to boost the immune system.

9. Effective against treatment of allergic rhinitis, Allergic conjunctis.

10. Improved adherence.

11. Less side effects.

12. Clinical benefits may occur more rapidly.

13. Combination therapy or more than one type treatment is the future is immunotherapy development. (10)

Challenges Occurs with Cancer Immunotherapy:

(11, 12, 13)

1. Development of the Pre-clinical Models That are Translate to Human Immunity System. (11, 12, 13):

Cancer drug discovery therapy and drug design always relies on preclinical data models study to prioritize drug targets and study mechanisms of action, delivery approaches, treatment dose and schedule, and safety management. The use of these models has led to many key discoveries in cancer treatment and immunotherapy, including the anti-tumour effects of CTLA-4 and programmed death-ligand 1/pro-grimed death-1 (PD-L1/PD-1) blockade However, human cancer immune biology is not always well reflected in the models that are typically used Major differences include composition of immune cells in the microenvironment, tumour antigens, and complexity of the immune cell suppression that are results from chronic immune recognition and exposure.

An issue with commonly occurs with pre-clinical models is that these rely on implantation of cancer cell lines which is difficult to determine. Tumours that are grow sub-sequent to implantation often do not recapitulate the tumour immune system contextual characteristics that influence an immune response in human cancers.

2. Determining the Dominant Drivers of Cancer: Immunity Systems (11, 12, 13):

Tumours are generally defined as inflamed based on high expression of PD-L1 by tumour cells or tumour-infiltrating immune cells and/or high prevalence of TILs. These inflamed tumours are may be associated with response to the immune system CPI, particularly PD-L1- and PD-1-directed antibodies. According to the Histopathological theory the T cells are interspersed in the intra-epithelial spaces, in close of proximity to and in contact with tumour cells A wealth of data now exists on biomarkers of inflamed tumours beyond tumour PD-L1, including IF Ng signatures, B cells, and genomic instability as defined by MSI or high tumour mutational burden (TMB). While IFNg signatures represent tumours with high PD-L1 expression and mark similar patient populations, the recent association of B cells with efficacy to CPIs underscores the importance of B cells in supporting T cell activation, survival, and anti-tumour immunity.

3. Understanding Organ-Specific Tumour (11, 12, 13):

Immune system Contexture At a rudimentary level of the dominant forces that are promote tumour growth include all tumours cell intrinsic properties and the organ in which the tumour resides. In metastatic urothelial carcinoma stage for instance there are two starkly divergent patterns of response emerge when considering the location of the metastasis. Tumours that metastasize to the liver in the body are more likely to resist therapy, whereas those that metastasize to the lymph nodes or lymph vessels are more likely to demonstrate complete responses to CPI. Thus, location is an important component of the equation associated with an anti-tumour immune response, or lack there of. The concept of tissue-specific immunity system is well appreciated in the contexts of infection and autoimmunity system, and increased consideration of the distinct immune system compartments and requirements within different tissues in cancer immunology, especially as related to the anti-tumour response, is warranted The liver, for example, is associated with the induction of immune tolerance through various mechanisms.

4. Understanding the Total Molecular and Cellular Drivers of Primary versus Secondary Immune Escape to Checkpoint Blockade Immunotherapies. (11, 12, 13):

Clinical experience with patients has shown that even when particular patients are well enabled to respond to CPIs then (e.g., high tumour PD-L1expression), a large percentage of them (>50%) do not respond to these agents. Opposite to that some patients experiencing clinical responses lasting years can still ultimately experience more progression of their cancer. And the former phenomenon is termed ‘‘primary immune escape’ ’and the latter, ‘‘secondary immune escape’’. While the other side mechanisms involved in these two different immune system escape phenomena (sometimes termed resistance) can overlap, they do not overlap temporally. Multi-omics analyses on tissues from patients on CPIs like atezolizumab, embryo lizumab, and nivolumab have now shed light on the many factors that contribute to immune escape.

5. Elucidating the Benefits of Endogenous versus Synthetic Immunity: (11, 12, 13):

The development of PD-L1/PD-1 inhibitors has enable to highly effective endogenous anti-cancer immune response to eliminate the cancer cells in many patients. This endogenous immune system response largely relies on the previously studied primed CD8+ T cells that specifically recognize cancer cells easily. These immune system cells can be either be re-invigorated or be expanded by PD-L1/PD-1 inhibition, leading to recognition cells and killing of cancer cells, as well as further proliferation of the T cells of immune.

Fig: Challenges of cancer immunotherapy.

6. Effective and Efficient Assessment to complete the Cancer Immunotherapy Combinations in Early-Phase Clinical Studies: (11, 12, 13):

With over 1,000 CIT combinations in the clinic there is a critical need to be able to assess these combinations as early as possible. Given the multiple steps involved the in anti cancer immunity system, the potential to enhance the CIT with rational combinations by modulating different biological steps in immunity systems, simultaneously or in rapid sequence is quite broad.

7. Full Characterization of the Impact of Steroids medicine and Immune Suppression on Cancer Immunotherapy and Autoimmune Toxicities: (11, 12, 13):

Corticosteroids drugs have a direct effect on human immunity Systems, affecting T cells more than B cells. The effect of drug on T cells are pleomorphic and vary by subset, with the net result being a reduction in the total number of T cells in circulation. As such, corticosteroids drug are routinely used in the treatment of auto-immune disease Of patients. They are also may used as a treat graft-versus-host disease and to reverse autoimmune system adverse events triggered by checkpoint inhibition or cytokine release syndrome (CRS) in synthetic immune approaches.

8. Maximize the Personalized Approaches with Composite Biomarkers

9. Developing well Improved Regulatory Endpoints for Cancer Immunotherapy

10. Optimizing Long-Term period Survival with Multi agent Cancer Immunotherapy Combination Regimens

CONCLUSION:

From these Review Paper, It is confirm that Immunotherapy is most essential therapy for the post cancer Immunity enhance. There are so many advantages of Immunotherapy and hence it is important and convenient method for human beings use. Due to its less side effect it is become essential for cancer patients. In future this topic of review paper will be most useful for further studies and research scientists.

ACKNOWLEDGEMENT:

With lots of respect to my family and my siblings, I would like to thank my college L.S.D.P College of Pharmacy for permitting me to do this review article work. I thankful to our Teachers Supriya Darandale mam for giving us there valuable time for the paper work guidance. I also thankful to publisher of Asian Journal of Pharmaceutical Research who gives me this opportunity to do work on review paper.

REFERENCE:

1. Aida Karachi, Immunotherapy for treatment of cancer. Intech open the words leading publication, 2018, 1-2.

2. Jeffrey koury, Mariana Lucero, Immunotherapes: Exploiting the immune system for cancer treatment. Journal of immunology research, 2018. 1 -2

3. James P. Allison, Tasuku Hongo.The Nobel prize in physiology or medicine, en.m.wikipedia.org, 2018.

4. G.D Enrico, H.L Machado. " A current perspective on Cancer immunotherapy. Clinical and translational medicine, 2017. Volume 6, 1:3

5. Pinto AC, Piccart-Gebhart M. Transtuzumab for patients with HER/2 positive breast cancer: Dilivery duration and combination therapies Breast, 2013. Volume 22: S152 - S155.

6. D.M.Pardoll, The blockade of immune checkpoint in cancer immunotherapy, Nature Review cancer, 2012. Volume 12: 4, 252- 264.

7. Brassil K J, Olsen M M, Chemotherapy and immunotherapy Guidelines and Recommendations for Practice, Oncology Nursing Society, 2019. 103-139.

8. Hongming Zhang, Jibei Chen, Current - Status and Future Direction of Cancer immunotherapy, Journal of cancer, 2018. volume 9 (10): 1773 - 1781.

9. Piniel M. Dimberu, Ralf M. Leonhardt, Cancer immunotherapy takes a multi - faceted Approach to kick the immune system into Gear, Yale Journal of Biology and medicine Dec. 2011; Volume 84 (4) : 371 - 380.

10. David H. Aggen, Charles G. Drake. Biomarkers for Immunotherapy in bladder cancer: a moving target. Journal for immunotherapy of cancer, 2017 volume 5: 9 - 13.

11. Priti S H and Daniel S. Top 10 challenges in cancer Immunotherapy. Cell Press, 2020 ; 52: 17-35.

12. Stanley J And Mohamed S. A cancer Immunotherapy: A brief Review of History, Possibilities, and Challenges Ahead. J cancer Metastasis. 2017; 3: 250-26125.

13. Lee C, Ventola M S. Cancer Immunotherapy Part3: Challengesa and future Trends. 2017; 42(8): 515-521.

Received on 02.04.2021 Modified on 16.09.2021

Asian J. Pharm. Res. 2022; 12(1):24-28.

DOI: 10.52711/2231-5691.2022.00005